Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linezolid + meropenem
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Linezolid + meropenem is a combination antibiotic therapy that pairs two different mechanisms of action. Linezolid is a synthetic oxazolydinone that inhibits protein synthesis by interacting with the 50S ribosomal subunit, while meropenem is a carbapenem antibiotic that interferes with bacterial cell wall synthesis. This combination has demonstrated synergistic effects against various bacterial infections, particularly against resistant Staphylococcus strains including linezolid-resistant and methicillin-resistant Staphylococcus aureus and S. epidermidis.
02
Targets
Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on linezolid + meropenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linezolid + meropenem.